Inhibition of selective adhesion molecules in treatment of inflammatory bowel disease.
Lymphocyte infiltration into the intestinal tract in inflammatory bowel disease (IBD) is mediated by interaction between α4 integrin and its specific ligands. Development of monoclonal antibodies against α4 integrin allowed targeting of lymphocyte trafficking into the intestine as a novel therapeutic intervention. Natalizumab, vedolizumab, alicaforsen AJM300, rhuMAb β7, CCX282-B, and PF-00547,659 are few of monoclonal antibodies that have shown high promise in trials with the potential for more attractive benefit:risk ratio than currently available therapies. In this review, an attempt is made to underline the therapeutic potential and the safety of anti-adhesion molecule treatment in IBD.
Dr. B.C. Roy College of Pharmacy and Allied Health Sciences, Durgapur, India. bhu nils@rediffmail.com
Nilanjan
N
Ghosh
Rituparna
R
Chaki
Subhash C
SC
Mandal
D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use*; D015815:Cell Adhesion Molecules / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000276:immunology; D002465:Cell Movement; D002986:Clinical Trials as Topic; D015870:Gene Expression / Q000276:immunology; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology / Q000473:pathology; D039441:Integrin alpha4 / Q000235:genetics / Q000276:immunology*; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D000069442:Natalizumab; D054735:Phosphorothioate Oligonucleotides / Q000494:pharmacology / Q000627:therapeutic use*; D018570:Risk Assessment
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015815:Cell Adhesion Molecules; D000069442:Natalizumab; D054735:Phosphorothioate Oligonucleotides; D039441:Integrin alpha4; C543529:vedolizumab; C559198:etrolizumab; C089753:alicaforsen